Novel deletion of SPAST in a Chinese family with hereditary spastic paraplegia

Share this Article

Singapore Med J 2013; 54(5): 251-254; http://dx.doi.org/10.11622/smedj.2013102
Novel deletion of SPAST in a Chinese family with hereditary spastic paraplegia

Feng YP, Ke X, Zhai M, Xin Q, Gong YQ, Liu QJ
Correspondence: Dr Qiji Liu, liuqiji@sdu.edu.cn

ABSTRACT
Introduction Hereditary spastic paraplegia (HSP) belongs to a large, heterogeneous group of progressive neurodegenerative diseases characterised by progressive lower extremity weakness and spasticity, which is caused by developmental failure or degeneration of motor axons in the corticospinal tract. Classical genetic studies have identified at least 46 genetic loci responsible for HSP.
Methods A genetic study was conducted on a four-generation Chinese family with autosomal dominant HSP. The SPAST gene was investigated using linkage analysis and direct sequencing. Findings were compared with unaffected family members and 50 normal, unaffected individuals who were matched for geographical ancestry.
Results We identified a novel 14-bp heterozygous deletion that induced a frameshift mutation in exon 15 of SPAST (SPG4). This mutation is predicted to have functional impact and found to cosegregate with the disease phenotype.
Conclusion Our results have expanded the mutation spectrum of the SPAST gene. These findings could help clinicians provide prenatal diagnosis of affected foetuses in families with a known history of such neurodegenerative diseases.

Keywords:  hereditary spastic paraplegia, mutation, spastin, SPG4
Singapore Med J 2013; 54(5): 251-254; http://dx.doi.org/10.11622/smedj.2013102

REFERENCES

1. Harding AE. Classification of the hereditary ataxias and paraplegias. Lancet 1983; 1:1151-5.
http://dx.doi.org/10.1016/S0140-6736(83)92879-9
 
2. Depienne C, Stevanin G, Brice A, Durr A. Hereditary spastic paraplegias: an update. Curr Opin Neurol 2007; 20:674-80.
http://dx.doi.org/10.1097/WCO.0b013e3282f190ba
 
3. Stevanin G, Ruberg M, Brice A. Recent advances in the genetics of spastic paraplegias. Curr Neurol Neurosci Rep 2008; 8:198-210.
http://dx.doi.org/10.1007/s11910-008-0032-z
 
4. Salinas S, Proukakis C, Crosby A, Warner TT. Hereditary spastic paraplegia: clinical features and pathogenetic mechanisms. Lancet Neurol 2008; 7:1127-38.
http://dx.doi.org/10.1016/S1474-4422(08)70258-8
 
5. Slabicki M, Theis M, Krastev DB, et al. A genome-scale DNA repair RNAi screen identifies SPG48 as a novel gene associated with hereditary spastic paraplegia. PLoS Biol 2010; 8:e1000408.
http://dx.doi.org/10.1371/journal.pbio.1000408
 
6. Fink JK. Hereditary spastic paraplegia. Curr Neurol Neurosci Rep 2006; 6:65-76.
http://dx.doi.org/10.1007/s11910-996-0011-1
 
7. Lin P, Li J, Liu Q, et al. A missense mutation in SLC33A1, which encodes the acetyl-CoA transporter, causes autosomal-dominant spastic paraplegia (SPG42). Am J Hum Genet 2008; 83:752-9.
http://dx.doi.org/10.1016/j.ajhg.2008.11.003
 
8. Meijer IA, Hand CK, Cossette P, Figlewicz DA, Rouleau GA. Spectrum of SPG4 mutations in a large collection of North American families with hereditary spastic paraplegia. Arch Neurol 2002; 59:281-6.
http://dx.doi.org/10.1001/archneur.59.2.281
 
9. Alvarez V, Sánchez-Ferrero E, Beetz C, et al. Mutational spectrum of the SPG4 (SPAST) and SPG3A (ATL1) genes in Spanish patients with hereditary spastic paraplegia. BMC Neurol 2010; 10:89.
 
10.The Human Gene Mutation Database [online]. Available at: www.hgmd.cf.ac.uk/ac/index.php. Accessed November 15, 2012.
 
11. Beetz C, Nygren AO, Schickel J, et al. High frequency of partial SPAST deletions in autosomal dominant hereditary spastic paraplegia. Neurology 2006; 67:1926-30.
http://dx.doi.org/10.1212/01.wnl.0000244413.49258.f5
 
12. Depienne C, Fedirko E, Forlani S, et al. Exon deletions of SPG4 are a frequent cause of hereditary spastic paraplegia. J Med Genet 2007; 44:281-4.
http://dx.doi.org/10.1136/jmg.2006.046425
 
13. Erichsen AK, Inderhaug E, Mattingsdal M, Eiklid K, Tallaksen CM. Seven novel mutations and four exon deletions in a collection of Norwegian patients with SPG4 hereditary spastic paraplegia. Eur J Neurol 2007; 14:809-14.
http://dx.doi.org/10.1111/j.1468-1331.2007.01861.x
 
14. Mitne-Neto M, Kok F, Beetz C, et al. A multi-exonic SPG4 duplication underlies sex-dependent penetrance of hereditary spastic paraplegia in a large Brazilian pedigree. Eur J Hum Genet 2007; 15:1276-9.
http://dx.doi.org/10.1038/sj.ejhg.5201924
 
15. Solowska JM, Garbern JY, Baas PW. Evaluation of loss of function as an explanation for SPG4-based hereditary spastic paraplegia. Hum Mol Genet 2010; 19:2767-79.
http://dx.doi.org/10.1093/hmg/ddq177
 
16. Errico A, Ballabio A, Rugarli EI. Spastin, the protein mutated in autosomal dominant hereditary spastic paraplegia, is involved in microtubule dynamics. Hum Mol Genet 2002; 11:153-63.
http://dx.doi.org/10.1093/hmg/11.2.153
PMid:11809724
 
17. Park SH, Zhu PP, Parker RL, Blackstone C. Hereditary spastic paraplegia proteins REEP1, spastin, and atlastin-1 coordinate microtubule interactions with the tubular ER network. J Clin Invest 2010; 120:1097-110.
http://dx.doi.org/10.1172/JCI40979
 
18. Mammalian Genotyping Service. Comprehensive human genetics maps (online). Available at: research.marshfieldclinic.org/genetics/GeneticResearch/compMaps.asp. Accessed November 14, 2012.
 
19. Harding AE. Hereditary "pure" spastic paraplegia: a clinical and genetic study of 22 families. J Neurol Neurosurg Psychiatry 1981; 44:871-83.
http://dx.doi.org/10.1136/jnnp.44.10.871
 
20. Harding AE. Hereditary spastic paraplegias. Semin Neurol 1993; 13:333-6.
http://dx.doi.org/10.1055/s-2008-1041143
 
21. Hazan J, Fonknechten N, Mavel D, et al. Spastin, a new AAA protein, is altered in the most frequent form of autosomal dominant spastic paraplegia. Nat Genet 1999; 23:296-303.
http://dx.doi.org/10.1038/15472
 
22. Fonknechten N, Mavel D, Byrne P, et al. Spectrum of SPG4 mutations in autosomal dominant spastic paraplegia. Hum Mol Genet 2000; 9:637-44.
http://dx.doi.org/10.1093/hmg/9.4.637
 
23. Patrono C, Casali C, Tessa A, et al. Missense and splice site mutations in SPG4 suggest loss-of-function in dominant spastic paraplegia. J Neurol 2002; 249:200-5.
http://dx.doi.org/10.1007/PL00007865
 
24. Charvin D, Cifuentes-Diaz C, Fonknechten N, et al. Mutations of SPG4 are responsible for a loss of function of spastin, an abundant neuronal protein localized in the nucleus. Hum Mol Genet 2003; 12:71-8
http://dx.doi.org/10.1093/hmg/ddg004

Opportunistic screening for colorectal neoplasia in Singapore using faecal immunochemical occult blood test

Share this Article

Singapore Med J 2013; 54(4): 220-223; http://dx.doi.org/10.11622/smedj.2013077
Opportunistic screening for colorectal neoplasia in Singapore using faecal immunochemical occult blood test

Tan WS, Tang CL, Koo WH
Correspondence: A/Prof Choong Leong Tang, tang.choong.leong@sgh.com.sg

ABSTRACT
Introduction The use of faecal immunochemical occult blood test (FIT) has been reported to decrease mortality  from colorectal cancer. The Singapore Cancer Society (SCS) gives out FIT kits to encourage opportunistic screening of colorectal cancer. Any Singapore citizen or permanent resident aged ≥ 50 years is eligible to receive two FIT kits. Participants with at least one positive FIT are referred for further evaluation. We aimed to analyse the results of SCS data from the year 2008.
Methods The factors evaluated included compliance, positive test rate (PR) and positive predictive value (PPV) of FIT. 
Results 20,989 participants received 41,978 kits in 2008. Compliance was 38.9%, with 8,156 participants returning at least one kit. 8% of participants tested positive, and 75% of these test-positive participants agreed to undergo further investigations. 33 participants had colorectal cancers, 45 had advanced polyps (≥ 1 cm) and 90 had polyps < 1 cm. Histologically, 114 polyps were adenomatous, 20 were hyperplastic and 1 was serrated. PPV of colorectal neoplasia for those who underwent further colonoscopy was 34%. Over half of the participants who had only one positive test had colorectal neoplasia.
Conclusion PR and PPV of FIT in our study were comparable to that in the literature. However, compliance was low and a quarter of all participants who tested positive refused further investigations. Extensive population education programmes are required to improve compliance and tackle inhibitions among the masses. It is also important to take steps to enhance the cost effectiveness of future screening programmes.

 

Keywords:colorectal cancer, faecal occult blood test, screening
Singapore Med J 2013; 54(4): 220-223; http://dx.doi.org/10.11622/smedj.2013077

REFERENCES

1. Seow A, Koh WP, Chia KS, et al. Trends in cancer incidence in Singapore, 1968-2002. Report No. 6. Singapore: Singapore Cancer Registry, 2004.
 
2. Mandel JS, Bond JH, Church TR, et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N Engl J Med 1993; 328:1365-71.
http://dx.doi.org/10.1056/NEJM199305133281901
 
3. Hardcastle J D, C hamberlain J O, R obinson M H, e t a l. R andomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet 1996; 348:1472-7.
http://dx.doi.org/10.1016/S0140-6736(96)03386-7
 
4. Kronborg O, Fenger C, Olsen J, Jorgensen OD, Sondergaard O. Randomised study of screening for colorectal cancer with faecal-occultblood test. Lancet 1996; 348:1467-71.
http://dx.doi.org/10.1016/S0140-6736(96)03430-7
 
5. Jorgensen OD, Kronborg O, Fenger C. A randomised study of screening for colorectal cancer using faecal occult blood testing: results after 13 years and seven biennial screening rounds. Gut 2002; 50:29-32.
http://dx.doi.org/10.1136/gut.50.1.29
 
6. Lindholm E, Brevinge H, Haglind E. Survival benefit in a randomized clinical trial of faecal occult blood screening for colorectal cancer. Br J Surg 2008; 95:1029-36.
http://dx.doi.org/10.1002/bjs.6136
 
7. Hewitson P, Glasziou P, Irwig L, Towler B, Watson E. Screening for colorectal cancer using the faecal occult blood test, Hemoccult. Cochrane Database Syst Rev 2007; 1:CD001216.
 
8. Goodyear SJ, Leung E, Menon A, et al. The effects of population-based faecal occult blood test screening upon emergency colorectal cancer admissions in Coventry and north Warwickshire. Gut 2008; 57:218-22.
http://dx.doi.org/10.1136/gut.2007.120253
 
9. Levi Z, Rozen P, Hazazi R, et al. A quantitative immunochemical fecal occult blood test for colorectal neoplasia. Ann Intern Med 2007; 146:244-55.
http://dx.doi.org/10.7326/0003-4819-146-4-200702200-00003
 
10. Vilkin A, Rozen P, Levi Z, et al. Performance characteristics and evaluation of an automated-developed and quantitative, immunochemical, fecal occult blood screening test. Am J Gastroenterol 2005; 100:2519-25.
http://dx.doi.org/10.1111/j.1572-0241.2005.00231.x
 
11. Fu WP, Kam MH, Ling WM, et al. Screening for colorectal cancer using a quantitative immunochemical faecal occult blood test: a feasibility study in an Asian population. Tech Coloproctol 2009; 13:225-30.
http://dx.doi.org/10.1007/s10151-009-0515-1
 
12. Allison JE, Sakoda LC, Levin TR, et al. Screening for colorectal neoplasms with new fecal occult blood tests: update on performance characteristics. J Natl Cancer Inst 2007; 99:1462-70.
http://dx.doi.org/10.1093/jnci/djm150
 
13. Burch JA, Soares-Weiser K, St John DJ, et al. Diagnostic accuracy of faecal occult blood tests used in screening for colorectal cancer: a systematic review. J Med Screen 2007; 14:132-7.
http://dx.doi.org/10.1258/096914107782066220
PMid:17925085
 
14. Chew MH, Suzanah N, Ho KS, et al. Colorectal cancer mass screening event utilising quantitative faecal occult blood test. Singapore Med J 2009; 50:348-53.
 
15. Chapple A, Ziebland S, Hewitson P, McPherson A. What affects the uptake of screening for bowel cancer using a faecal occult blood test (FOBt): a qualitative study. Soc Sci Med 2008; 66:2425-35.
http://dx.doi.org/10.1016/j.socscimed.2008.02.009
 
16. Birkenfeld S, Belfer RG, Chared M, et al. Factors affecting compliance in faecal occult blood testing: a cluster randomized study of the faecal immunochemical test versus the guaiac faecal occult test. J Med Screen 2011; 18:135-41.
http://dx.doi.org/10.1258/jms.2011.010147
 
17. Ciatto S, Martinelli F, Castiglione G, et al. Association of FOBT-assessed faecal Hb content with colonic lesions detected in the Florence screening programme. Br J Cancer 2007; 96:218-21.
http://dx.doi.org/10.1038/sj.bjc.6603534
 
18. Castiglione G, Grazzini G, Ciatto S. Guaiac and immunochemical tests for faecal occult blood in colorectal cancer screening. Br J Cancer 1992; 65:942-4.
http://dx.doi.org/10.1038/bjc.1992.197
PMid:1616868 PMCid:1977762
 
19. Castiglione G, Sala P, Ciatto S, et al. Comparative analysis of results of guaiac and immunochemical tests for faecal occult blood in colorectal cancer screening in two oncological institutions. Eur J Cancer Prev 1994; 3:399-405.
http://dx.doi.org/10.1097/00008469-199409000-00003
 
20. Denis B, Ruetsch M, Strentz P, et al. Short term outcomes of the first round of a pilot colorectal cancer screening programme with guaiac based faecal occult blood test. Gut 2007; 56:1579-84.
http://dx.doi.org/10.1136/gut.2007.126037
 
21. Guittet L, Bouvier V, Mariotte N, et al. Performance of immunochemical faecal occult blood test in colorectal cancer screening in average-risk population according to positivity threshold and number of samples. Int J Cancer 2009; 125:1127-33.
http://dx.doi.org/10.1002/ijc.24407
 
22. Do C, Bertrand C, Palasse J, et al. A new biomarker that predicts colonic neoplasia outcome in patients with hyperplastic colonic polyps. Cancer Prev Res (Phila) 2012; 5:675-84.
http://dx.doi.org/10.1158/1940-6207.CAPR-11-0408

Does pulse oximetry accurately monitor a patient's ventilation during sedated endoscopy under oxygen supplementation?

Share this Article

Singapore Med J 2013; 54: 212-215; http://dx.doi.org/10.11622/smedj.2013075
Does pulse oximetry accurately monitor a patient's ventilation during sedated endoscopy under oxygen supplementation?

Arakawa H, Kaise M, Sumiyama K, Saito S, Suzuki T, Tajiri H
Correspondence: Dr Hiroshi Arakawa, endosc-arakawa@jikei.ac.jp

 

ABSTRACT
Introduction Pulse oximetry (SpO2) measures oxygen saturation but not alveolar ventilation. Its failure to detect alveolar hypoventilation during sedated endoscopy under oxygen supplementation has been reported. The aim of this study was to measure the masking effect of oxygen supplementation in SpO2 when alveolar hypoventilation develops during sedated endoscopy.
Methods A total of 70 patients undergoing sedated diagnostic colonoscopy were randomly divided into two groups – oxygen supplementation group (n = 35) and room air breathing group (n = 35). SpO2 and end-tidal carbon dioxide (etCO2) were measured by non-intubated capnography during the procedure for all the patients.
Results The rise of etCO2 caused by alveolar hypoventilation was comparable in the two groups after sedation. SpO2 was significantly higher in the oxygen supplementation group than in the room air breathing group (98.6% ± 1.4% vs. 93.1% ± 2.9%; p < 0.001) at peak etCO2, and oxygen supplementation caused SpO2 to be overestimated by greater than 5% when compared with room air. SpO2 at peak etCO2 was reduced from the baseline before sedation for the oxygen supplementation and room air breathing groups by 0.5% ± 1.1% and 4.1% ± 3.1%, respectively (p < 0.001).
Conclusion SpO2 alone is not adequate for monitoring alveolar ventilation during sedated endoscopy under oxygen supplementation due to possible delays in detecting alveolar hypoventilation in patients. Even if SpO2 decreases by only 1% during the procedure and its level remains near 100%, physicians should consider the onset of severe alveolar hypoventilation, which requires immediate intervention.

Keywords: capnography, endoscopy, hypoventilation, pulse oximetry, sedation
Singapore Med J 2013; 54: 212-215; http://dx.doi.org/10.11622/smedj.2013075

REFERENCES

1. Hutton P, Clutton-Brock T. The benefits and pitfalls of pulse oximetry. BMJ 1993; 307:457-8.
http://dx.doi.org/10.1136/bmj.307.6902.457
 
2. Davidson JAH, Hosie HE. Limitations of pulse oximetry: respiratory insufficiency – a failure of detection. BMJ 1993; 307:372-3.
http://dx.doi.org/10.1136/bmj.307.6900.372
 
3. Freeman ML, Hennessy JT, Cass OW, Pheley AM. Carbon dioxide retention and oxygen desaturation during gastrointestinal endoscopy. Gastroenterology 1993; 105:331-9.
 
4. Waring JP, Baron TH, Hirota WK, American Society for Gastrointestinal Endoscopy, Standards of Practile Committee, et al Guidelines for conscious sedation and monitoring during gastrointestinal endoscopy. Gastrointest Endosc 2003; 58:317-22.
http://dx.doi.org/10.1067/S0016-5107(03)00001-4
 
5. Fu ES, Downs JB, Schweiger JW, Miguel RV, Smith RA. Supplemental oxygen impares detection of hypoventilation by pulse oximetry. Chest 2004; 126:1552-8.
http://dx.doi.org/10.1378/chest.126.5.1552
 
6. Vargo JJ, Zuccaro G Jr, Dumot JA, et al. Automated graphic assessment of respiratory activity is superior to pulse oximetry and visual assessment for the detection of early respiratory depression during therapeutic upper endoscopy. Gastrointest Endosc 2002; 55:826-31.
http://dx.doi.org/10.1067/mge.2002.124208
 
7. Lightdale JR, Goldmann DA, Feldman HA, et al. Microstream capnography improves patient monitoring during moderate sedation: a randomized controlled trial. Pediatrics 2006; 117:e1170-8.
http://dx.doi.org/10.1542/peds.2005-1709
 
8. Thompson AM, Wright DJ, Murray W, et al. Analysis of 153 deaths after upper gastrointestinal endoscopy: room for improvement? Surg Endosc 2004; 18:22-5.
http://dx.doi.org/10.1007/s00464-003-9069-x
 
9. Freeman ML, Nelson DB, Sherman S, et al. Complication of endoscopic biliary sphincterotomy. N Engl J Med 1996; 335:909-18.
http://dx.doi.org/10.1056/NEJM199609263351301
 
10.Yoshino J. [5th report of endoscopic complication: results of the Japan Gastroenterological Endoscopy Society survey from 2003 to 2007]. Gastroenterol Endosc 2010; 52:95-103. Japanese.
 
11. Miner JR, Heegaard W, Plummer D. End-tidal carbon dioxide monitoring during procedural sedation. Acad Emerg Med 2002; 9:275-80.
http://dx.doi.org/10.1111/j.1553-2712.2002.tb01318.x
 
12. Waugh JB, Epps CA, Khodneva YA. Capnography enhances surveillance of respiratory events during procedural sedation: a meta-analysis. J Clin Anesth 2011; 23:189-96.
http://dx.doi.org/10.1016/j.jclinane.2010.08.012
 
13. Koniaris LG, Wilson S, Drugas G, Simmons W. Capnographic monitoring of ventilatory status during moderate (conscious) sedation. Surg Endosc 2003; 17:1261-5.
http://dx.doi.org/10.1007/s00464-002-8789-7
 
14. Patel S, Vargo JJ, Khandwala F, et al. Deep sedation occurs frequently during elective endoscopy with meperidine and midazolam. Am J Gastroenterol 2005; 100:2689-95.
http://dx.doi.org/10.1111/j.1572-0241.2005.00320.x
 
15. Qadeer MA, Vargo JJ, Dumot JA, et al. Capnographic monitoring of respiratory activity improves safety of sedation for endoscopic cholangiopancreatography and ultrasonography. Gastroenterology 2009; 136:1568-76.
http://dx.doi.org/10.1053/j.gastro.2009.02.004
 
16.Bell GD, McCloy RF, Charlton JE, et al. Recommendations for standards of sedation and patient monitoring during gastrointestinal endoscopy. Gut 1991; 32:823-7.
http://dx.doi.org/10.1136/gut.32.7.823
 
17. American Society of Anesthesiologists Task Force on Sedation and Analgesia by Non-Anesthesiologists. Practice guidelines for sedation and analgesia by non-anesthesiologist. Anesthesiology 2002; 96:1004-17.
http://dx.doi.org/10.1097/00000542-200204000-00031
 
18. Standards of practice committee of the American Society for Gastrointestinal Endoscopy. Sedation and anesthesia in GI endoscopy. Gastrointest Endosc 2008; 68:815-26.

Direct endoscopic necrosectomy: a minimally invasive endoscopic technique for the treatment of infected walled-off pancreatic necrosis and infected pseudocysts with solid debris

Share this Article

Singapore Med J 2013; 54: 206-211; http://dx.doi.org/10.11622/smedj.2013074
Direct endoscopic necrosectomy: a minimally invasive endoscopic technique for the treatment of infected walled-off pancreatic necrosis and infected pseudocysts with solid debris

Ang TL, Kwek AB, Tan SS, Ibrahim S, Fock KM, Teo EK
Correspondence: Adj A/Prof Ang Tiing Leong, tiing_leong_ang@cgh.com.sg

ABSTRACT
Introduction Endoscopic transenteric stenting is the standard treatment for pseudocysts, but it may be inadequate for treating infected collections with solid debris. Surgical necrosectomy results in significant morbidity. Direct endoscopic necrosectomy (DEN), a minimally invasive treatment, may be a viable option. This study examined the efficacy and safety of DEN for the treatment of infected walled-off pancreatic necrosis and infected pseudocysts with solid debris.
Methods This study was a retrospective analysis of data collected from a prospective database of patients who underwent DEN in the presence of infected walled-off pancreatic necrosis or infected pseudocysts with solid debris from April 2007 to October 2011. DEN was performed as a staged procedure. Endoscopic ultrasonography-guided transgastric stenting was performed during the first session for initial drainage and to establish endoscopic access to the infected collection. In the second session, the drainage tract was dilated endoscopically to allow transgastric passage of an endoscope for endoscopic necrosectomy. Outcome data included technical success, clinical success and complication rates.
Results Eight patients with infected walled-off pancreatic necrosis or infected pseudocysts with solid debris (mean size 12.5 cm; range 7.8–17.2 cm) underwent DEN. Underlying aetiologies included severe acute pancreatitis (n = 6) and post-pancreatic surgery (n = 2). DEN was technically successful in all patients. Clinical resolution was achieved in seven patients. One patient with recurrent collection opted for surgery instead of repeat endotherapy. No procedural complications were encountered.
Conclusion DEN is a safe and effective minimally invasive treatment for infected walled-off pancreatic necrosis and infected pseudocysts.

Keywords: debridement, endoscopic drainage, infected pseudocyst, pancreatic necrosis
Singapore Med J 2013; 54: 206-211; http://dx.doi.org/10.11622/smedj.2013074

REFERENCES

1. Seewald S, Ang TL, Teng KC, Soehendra N. EUS-guided drainage of pancreatic pseudocysts, abscesses and infected necrosis. Dig Endosc 2009; 21(1 suppl):S61-5.
http://dx.doi.org/10.1111/j.1443-1661.2009.00860.
 
2. Seewald S, Ang TL, Kida M, Teng KY, Soehendra N. EUS 2008 Working Group document: evaluation of EUS-guided drainage of pancreatic-fluid collections (with video). Gastrointest Endosc 2009; 69(2 suppl):S13-21.
http://dx.doi.org/10.1016/j.gie.2008.10.061
 
3. Varadarajulu S, Lopes TL, Wilcox CM, et al. EUS versus surgical cystgastrostomy for management of pancreatic pseudocysts. Gastrointest Endosc 2008; 68:649-55.
http://dx.doi.org/10.1016/j.gie.2008.02.057
 
4. Hookey LC, Debroux S, Delhaye M, et al. Endoscopic drainage of pancreatic-fluid collections in 116 patients: a comparison of etiologies, drainage techniques, and outcomes. Gastrointest Endosc 2006; 63:635-43.
http://dx.doi.org/10.1016/j.gie.2005.06.028
 
5. Gardner TB, Chahal P, Papachristou GI, et al. A comparison of direct endoscopic necrosectomy with transmural endoscopic drainage for the treatment of walled-off pancreatic necrosis. Gastrointest Endosc 2009; 69:1085-94.
http://dx.doi.org/10.1016/j.gie.2008.06.061
 
6. Seifert H, Wehrmann T, Schmitt T, Zeuzem S, Caspary WF. Retroperitoneal endoscopic debridement for infected peripancreatic necrosis. Lancet 2000; 356:653-5.
http://dx.doi.org/10.1016/S0140-6736(00)02611-8
 
7. Seewald S, Groth S, Omar S, et al. Aggressive endoscopic therapy for pancreatic necrosis and pancreatic abscess: a new safe and effective treatment algorithm. Gastrointest Endosc 2005; 62:92-100.
http://dx.doi.org/10.1016/S0016-5107(05)00541-9
 
8. Bollen TL, Besselink MG, van Santvoort HC, Gooszen HG, van Leeuwen MS. Toward an update of the atlanta classification on acute pancreatitis: review of new and abandoned terms. Pancreas 2007; 35:107-13.
http://dx.doi.org/10.1097/mpa.0b013e31804fa189
 
9. Ang TL, Teo EK, Fock KM. EUS-guided drainage of infected pancreatic pseudocyst: use of a 10F Soehendra dilator to facilitate a double-wire technique for initial transgastric access (with videos). Gastrointest Endosc 2008; 68:192-4.
http://dx.doi.org/10.1016/j.gie.2007.11.018
 
10. Rodriguez JR, Razo AO, Targarona J, et al. Debridement and closed packing for sterile or infected necrotizing pancreatitis: insights into indications and outcomes in 167 patients. Ann Surg 2008; 247:294-9.
http://dx.doi.org/10.1097/SLA.0b013e31815b6976
 
11. Besselink MG, Verwer TJ, Schoenmaeckers EJ, et al. Timing of surgical intervention in necrotizing pancreatitis. Arch Surg 2007; 142:1194-1201.
http://dx.doi.org/10.1001/archsurg.142.12.1194
 
12. Vege SS, Baron TH. Management of pancreatic necrosis in severe acute pancreatitis. Clin Gastroenterol Hepatol 2005; 3:192-6.
http://dx.doi.org/10.1016/S1542-3565(04)00668-8
 
13. Uhl W, Warshaw A, Imrie C, et al. IAP Guidelines for the Surgical Management of Acute Pancreatitis. Pancreatology 2002; 2:565-73.
http://dx.doi.org/10.1159/000071269
 
14. van Santvoort HC, Besselink MG, Bakker OJ, et al. A step-up approach or open necrosectomy for necrotizing pancreatitis. N Engl J Med 2010; 362:1491-502.
http://dx.doi.org/10.1056/NEJMoa0908821
 
15. Babu BI, Siriwardena AK. Current status of minimally invasive necrosectomy for post-inflammatory pancreatic necrosis. HPB (Oxford) 2009; 11:96-102.
http://dx.doi.org/10.1111/j.1477-2574.2009.00041.x
 
16. Parikh PY, Pitt HA, Kilbane M, et al. Pancreatic necrosectomy: North American mortality is much lower than expected. J Am Coll Surg 2009; 209:712-9.
http://dx.doi.org/10.1016/j.jamcollsurg.2009.08.009
 
17. Papachristou GI, Takahashi N, Chahal P, Sarr MG, Baron TH. Peroral endoscopic drainage/debridement of walled-off pancreatic necrosis. Ann Surg 2007; 245:943-51.
http://dx.doi.org/10.1097/01.sla.0000254366.19366.69
 
18. Charnley RM, Lochan R, Gray H, et al. Endoscopic necrosectomy as primary therapy in the management of infected pancreatic necrosis. Endoscopy 2006; 38:925-8.
http://dx.doi.org/10.1055/s-2006-944731
 
19. Seifert H, Biermer M, Schmitt W, et al. Transluminal endoscopic necrosectomy after acute pancreatitis: a multicentre study with long-term follow-up (the GEPARD Study). Gut 2009; 58:1260-6.
http://dx.doi.org/10.1136/gut.2008.163733
 
20. Gardner TB, Coelho-Prabhu N, Gordon SR, et al. Direct endoscopic necrosectomy for the treatment of walled-off pancreatic necrosis: results from a multicenter U.S. series. Gastrointest Endosc 2011; 73:718-26.
http://dx.doi.org/10.1016/j.gie.2010.10.053
 
21. Seewald S, Ang TL, Richter H, et al. Long-term results after endoscopic drainage and necrosectomy of symptomatic pancreatic fluid collections. Dig Endosc 2012; 24:36-41.
http://dx.doi.org/10.1111/j.1443-1661.2011.01162.x
 
22. Bakker OJ, Van Sanvoort HC, van Brunschot S, et al. Endoscopic transgastric vs surgical necrosectomy for infected necrotizing pancreatitis: a randomized trial. JAMA 2012; 307:1053-61.
http://dx.doi.org/10.1001/jama.2012.276
 
23. Fink D, Soares R, Matthews JB, Alverdy JC. History, goals, and technique of laparoscopic pancreatic necrosectomy. J Gastrointest Surg 2011; 15:1092-7.
http://dx.doi.org/10.1007/s11605-011-1506-x
 
24. Gluck M, Ross A, Irani S, et al. Endoscopic and percutaneous drainage of symptomatic walled-off pancreatic necrosis reduces hospital stay and radiographic resources. Clin Gastroenterol Hepatol 2010; 8:1083-8.
http://dx.doi.org/10.1016/j.cgh.2010.09.010
 
25. Nealon WH, Bhutani M, Riall TS, et al. A unifying concept: pancreatic ductal anatomy both predicts and determines the major complications resulting from pancreatitis. J Am Coll Surg 2009; 208:790-9.
http://dx.doi.org/10.1016/j.jamcollsurg.2008.12.027
 
26. Telford JJ, Farrell JJ, Saltzman JR, et al. Pancreatic stent placement for duct disruption. Gastrointest Endosc 2002; 56:18-24.
http://dx.doi.org/10.1067/mge.2002.125107
 
27. Seewald S, Brand B, Groth S, et al. Endoscopic sealing of pancreatic fistula by using N-butyl-2-cyanoacrylate. Gastrointest Endosc 2004; 59:463-70.
http://dx.doi.org/10.1016/S0016-5107(03)02708-1
 
28. Ang TL, Teo EK, Fock KM. Endoscopic drainage and endoscopic necrosectomy in the management of symptomatic pancreatic collections. J Dig Dis 2009; 10:213-24.
http://dx.doi.org/10.1111/j.1751-2980.2009.00388.x
 
29. Arvanitakis M, Delhaye M, Bali MA, et al. Pancreatic-fluid collections: a randomized controlled trial regarding stent removal after endoscopic transmural drainage. Gastrointest Endosc 2007; 65:609-19.
http://dx.doi.org/10.1016/j.gie.2006.06.083

Lifetime cost-effectiveness analysis of ticagrelor in patients with acute coronary syndromes based on the PLATO trial: a Singapore healthcare perspective

Share this Article

Singapore Med J 2013; 54(3): 169-175; http://dx.doi.org/doi:10.11622/smedj.2013045
Lifetime cost-effectiveness analysis of ticagrelor in patients with acute coronary syndromes based on the PLATO trial: a Singapore healthcare perspective

Chin CT, Mellstrom C, Chua TS, Matchar DB
Correspondence: Dr Chin Chee Tang, chin.chee.tang@nhcs.com.sg

ABSTRACT
Introduction Ticagrelor is a novel antiplatelet drug developed to reduce atherothrombosis. The PLATO trial compared ticagrelor and aspirin to clopidogrel and aspirin in patients with acute coronary syndromes (ACS). Ticagrelor was found to be superior in the primary composite endpoint of cardiovascular death, myocardial infarction or stroke, without increasing major bleeding events. The current study estimates the lifetime cost-effectiveness of ticagrelor relative to generic clopidogrel from a Singapore public healthcare perspective.
Methods This study used a two-part cost-effectiveness model. The first part was a 12-month decision tree (using PLATO trial data) to estimate the rates of major cardiovascular events, healthcare costs and health-related quality of life. The second part was a Markov model estimating lifetime quality-adjusted survival and costs conditional on events during the initial 12 months. Daily drug costs applied were SGD 1.05 (generic clopidogrel) and SGD 6.00 (ticagrelor). Cost per quality-adjusted life years (QALY) was estimated from a Singapore public healthcare perspective using life tables and short-term costs from Singapore, and long-term costs from South Korea. Deterministic and probabilistic sensitivity analyses were performed.
Results Ticagrelor was associated with a lifetime QALY gain of 0.13, primarily driven by lower mortality. The resulting incremental cost per QALY gained was SGD 10,136.00. Probabilistic sensitivity analysis indicated that ticagrelor had a > 99% probability of being cost-effective, given the lower recommended WHO willingness-to-pay threshold of one GDP/capita per QALY.
Conclusion Based on PLATO trial data, one-year treatment with ticagrelor versus generic clopidogrel in patients with ACS, relative to WHO reference standards, is cost-effective from a Singapore public healthcare perspective.

Keywords: acute coronary syndromes, clopidogrel, cost-effectiveness, Singapore, ticagrelor
Singapore Med J 2013; 54(3): 169-175; doi:10.11622/smedj.2013045

REFERENCES

1. National Registry of Diseases. Information paper on acute myocardial infarction in Singapore, 2007-2008. Available at: http://www.nrdo.gov.sg/uploadedFiles/NRDO/Publications/20110211AMIInform.... Accessed January 7, 2013.
 
2. Chan MY, Shah BR, Gao F, et al. Recalibration of the Global Registry of Acute Coronary Events risk score in a multiethnic Asian population. Am Heart J 2011; 162:291-9.
http://dx.doi.org/10.1016/j.ahj.2011.05.016
 
3. 2012 Writing Committee Members, Jneid H, Anderson JL, et al. 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/Non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2012; 126:875-910.
 
4. Kushner FG, Hand M, Smith SC Jr, et al. 2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (updating the 2005 Guideline and 2007 Focused Update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2009; 120:2271-306.
http://dx.doi.org/10.1161/CIRCULATIONAHA.109.192663
 
5. Hamm CW, Bassand JP, Agewall S, et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2011; 32:2999-3054.
http://dx.doi.org/10.1093/eurheartj/ehr236
 
6. Steg PG, James SK, Atar D, et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). Eur Heart J 2012; 33:2569-619.
http://dx.doi.org/10.1093/eurheartj/ehs215
 
7. Husted S, Emanuelsson H, Heptinstall S, et al. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur Heart J 2006; 27:1038-47.
http://dx.doi.org/10.1093/eurheartj/ehi754
 
8. James S, Akerblom A, Cannon CP, et al. Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial. Am Heart J 2009; 157:599-605.
http://dx.doi.org/10.1016/j.ahj.2009.01.003
 
9. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361:1045-57.
http://dx.doi.org/10.1056/NEJMoa0904327
PMid:19717846
 
10. Nikolic E, Janzon M, Hauch O, et al. Cost-effectiveness of treating acute coronary syndrome patients with ticagrelor for 12 months: results from the PLATO study. Eur Heart J 2013; 34:220-8. Epub June 19, 2012.
http://dx.doi.org/10.1093/eurheartj/ehs149
 
11. Norhammar A, Stenestrand U, Lindback J, Wallentin L. Women younger than 65 years with diabetes mellitus are a high-risk group after myocardial infarction: a report from the Swedish Register of Information and Knowledge about Swedish Heart Intensive Care Admission (RIKS-HIA). Heart 2008; 94:1565-70.
http://dx.doi.org/10.1136/hrt.2007.135038
 
12. Dennis MS, Burn JP, Sandercock PA, et al. Longterm survival after first-ever stroke: the Oxfordshire Community Stroke Project. Stroke 1993; 24:796-800.
http://dx.doi.org/10.1161/01.STR.24.6.796
 
13. Olai L, Omne-Ponten M, Borgquist L, Svardsudd K. Survival, hazard function for a new event, and healthcare utilization among stroke patients over 65 years old. Stroke 2009; 40:3585-90.
http://dx.doi.org/10.1161/STROKEAHA.109.556720
 
14. Ministry of Health, Singapore. Hospital Bill Sizes. Available at: http://www.moh.gov.sg/content/moh_web/home/costs_and_financing/HospitalB.... Accessed January 7, 2013.
 
15. Management Center for Health Promotion, Republic of Korea. Costeffectiveness analysis of national prevention programs for cardiovascular disease, 2007.
 
16. Burström K, Johannesson M, Rehnberg C. Deteriorating health status in Stockholm 1998-2002: results from repeated population surveys using the EQ-5D. Qual Life Res 2007;16:1547-53.
http://dx.doi.org/10.1007/s11136-007-9243-z
 
17. Department of Statistics, Singapore. Complete Life Tables 2006-2011 for Singapore Resident Population. Available at: http://www.singstat.gov.sg/pubn/popn/lifetable06-11.pdf. Accessed January 7, 2013.
 
18.Gold MR, Patrick DL, Torrance GW, et al. Identifying and valuing outcomes. In: Gold MR, Siegel JE, Russell LB, Weinstein MC, eds. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press, 1996.
 
19. Sachs JD. Macroeconomics and Health: Investing in Health for Economic Development. Report of the Commision on Macroeconomics and Health. Geneva, Switzerland: World Health Organisation, 2001. Available at: http://whqlibdoc.who.int/publications/2001/924154550x.pdf. Accessed January 7, 2013.
 
20. World Health Organization. Global Health Observatory Data Repository. Available at: http://apps.who.int/ghodata/?theme=country. Accessed January 7, 2013.
 
21. Ministry of Health, Singapore. Costs and Financing. Available at: http://www.moh.gov.sg/content/moh_web/home/costs_and_financing.html. Accessed January 7, 2013.
 
22. Mahaffey KW, Wojdyla DM, Carroll K, et al. Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation 2011; 124:544-54.
http://dx.doi.org/10.1161/CIRCULATIONAHA.111.047498
 
23. Serebruany VL. Viewpoint: paradoxical excess mortality in the PLATO trial should be independently verified. Thromb Haemost 2011; 105:752-9.
http://dx.doi.org/10.1160/TH10-12-0807
 
24. Ohman EM, Roe MT. Explaining the unexpected: insights from the PLATelet inhibition and clinical Outcomes (PLATO) trial comparing ticagrelor and clopidogrel (editorial). Thromb Haemost 2011; 105:763-5.
http://dx.doi.org/10.1160/TH11-03-0159
 

Cervical screening uptake and its predictors among rural women in Malaysia

Share this Article

Singapore Med J 2013; 54(3): 163-168; http://dx.doi.org/doi:10.11622/smedj.2013047
Cervical screening uptake and its predictors among rural women in Malaysia

Gan DE, Dahlui M
Correspondence: Dr Maznah Dahlui, maznahd@ummc.edu.my

ABSTRACT
Introduction Cervical cancer is the third most common cancer among Malaysian women. However, the uptake of cervical cancer screening – Pap smear – by women in Malaysia has been low and remains a challenge. This study was conducted to assess the cervical screening practices of rural women in Malaysia and to examine the factors associated with such practices.
Methods A cross-sectional survey was conducted in five rural districts in Perak, Malaysia. 1,000 households were selected through multistage random sampling. Women aged 20–64 years were interviewed by trained enumerators using structured questionnaires. Binomial logistic regression was used to identify predictors of cervical screening through univariate and multivariate analyses.
Results Among the 959 respondents, only 48.9% had undergone Pap smear at least once in the past three years. Women in the age group 40–49 years (odds ratio 3.027, 95% confidence interval 1.546–5.925; p < 0.005) were found to be significantly more likely to attend cervical cancer screening as compared to those in the age group 20–29 years. Other significant predictors were being married with children, having knowledge of cervical cancer symptoms, receiving relevant information regarding cervical cancer from health personnel or campaigns, being engaged in family planning and receiving encouragement from husbands.
Conclusion Efforts to boost the uptake of Pap smear screening among the rural population should be targeted toward the predictors of positive uptake.

Keywords: cervical screening practices, Pap smear, predictors
Singapore Med J 2013; 54(3): 163-168; doi:10.11622/smedj.2013047

REFERENCES

1. Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127:2893-917.
http://dx.doi.org/10.1002/ijc.25516
 
2. Ministry of Health Malaysia. Malaysia Cancer Statistics-Data and Figure 2007. Malaysia: National Cancer Registry Report, 2011.
 
3. Forouzanfar MH, Foreman KJ, Delossantos AM, et al. Breast and cervical cancer in 187 countries between 1980 and 2010: a systematic analysis. Lancet 2011; 378:1461-84.
http://dx.doi.org/10.1016/S0140-6736(11)61351-2
 
4. Ministry of Health Malaysia. Clinical Practice Guidelines: Management of Cervical Cancer. Malaysia: Ministry of Health Malaysia, 2003.
 
5. Ministry of Health Malaysia. The Third National Health and Morbidity Survey (NHMS III) 2006, Volume 2. Institute for Public Health (IPH), 2008.
 
6. Chee HL, Rashidah S, Shamsuddin K, Intan O. Factors related to the practice of breast self examination (BSE) and Pap smear screening among Malaysian women workers in selected electronics factories. BMC Womens Health 2003; 3:3.
http://dx.doi.org/10.1186/1472-6874-3-3
 
7. Abdullah F, Aziz NA, Su TT. Factors related to poor practice of Pap smear screening among secondary school teachers in Malaysia. Asian Pac J Cancer Prev 2011; 12:1347-52.
PMid:21875295
 
8. Tan YY, Hesham R, Qodriyah HM. Knowledge and attitude of university students in health sciences on the prevention of cervical cancer. Med J Malaysia 2010; 65:53-7.
PMid:21265250
 
9. Denny L, Quinn M, Sankaranarayanan R. Chapter 8: Screening for cervical cancer in developing countries. Vaccine 2006; 24 suppl 3:S3/71-7.
 
10. Blomberg K, Tishelman C, Ternestedt BM, et al. How can young women be encouraged to attend cervical cancer screening? Suggestions from faceto-face and internet focus group discussions with 30-year-old women in Stockholm, Sweden. Acta Oncol 2011; 50:112-20.
http://dx.doi.org/10.3109/0284186X.2010.528790
 
11. Department of Statistics Malaysia. Population Distribution by Local Authority Areas and Mukims, 2010 [online]. Available at: www.statistics.gov.my/portal_lama/download_Population/files/population/0.... Accessed January 22, 2013.
 
12. Rebolj M, van Ballegooijen M, Berkers LM, Habbema D. Monitoring a national cancer prevention program: successful changes in cervical cancer screening in the Netherlands. Int J Cancer 2007; 120:806-12.
http://dx.doi.org/10.1002/ijc.22167
 
13. Leung SS, Leung I. Cervical cancer screening: knowledge, health perception and attendance rate among Hong Kong Chinese women. Int J Womens Health 2010; 2:221-8.
http://dx.doi.org/10.2147/IJWH.S10724
 
14. Al-Naggar RA, Low WY, Isa ZM. Knowledge and barriers towards cervical cancer screening among young women in Malaysia. Asian Pac J Cancer Prev 2010; 11:867-73.
PMid:21133593
 
15. Paolino M, Arrossi S. Women's knowledge about cervical cancer, Pap smear and human papillomavirus and its relation to screening in Argentina. Women Health 2011; 51:72-87.
http://dx.doi.org/10.1080/03630242.2010.542547
 
16. Uysal A, Birsel A. Knowledge about cervical cancer risk factors and pap testing behaviour among Turkish women. Asian Pac J Cancer Prev 2009; 10:345-50.
PMid:19640170
 
17. Liao CC, Wang HY, Lin RS, Hsieh CY, Sung FC. Addressing Taiwan's high incidence of cervical cancer: factors associated with the Nation's low compliance with Papanicolaou screening in Taiwan. Public Health 2006; 120:1170-6.
http://dx.doi.org/10.1016/j.puhe.2006.07.028
 
18. Erbil N, Tezcan Y, Gür EN, Yildirim M, Ali? N. Factors affecting cervical screening among Turkish women. Asian Pac J Cancer Prev 2010; 11:1641-4.
PMid:21338210
 
19. Kivistik A, Lang K, Baili P, Anttila A, Veerus P. Women's knowledge about cervical cancer risk factors, screening, and reasons for non-participation in cervical cancer screening programme in Estonia. BMC Womens Health 2011; 11:43.
http://dx.doi.org/10.1186/1472-6874-11-43
 
20. Hansen BT, Hukkelberg SS, Haldorsen T, et al. Factors associated with nonattendance, opportunistic attendance and reminded attendance to cervical screening in an organized screening program: a cross-sectional study of 12,058 Norwegian women. BMC Public Health 2011; 11:264.
http://dx.doi.org/10.1186/1471-2458-11-264
 
21. Lofters AK, Moineddin R, Hwang SW, Glazier RH. Predictors of low cervical cancer screening among immigrant women in Ontario, Canada. BMC Womens Health 2011; 11:20.
http://dx.doi.org/10.1186/1472-6874-11-20
 
22. Brouwers MC, De Vito C, Bahirathan L, et al. Effective interventions to facilitate the uptake of breast, cervical and colorectal cancer screening: an implementation guideline. Implement Sci 2011; 6:112.
http://dx.doi.org/10.1186/1748-5908-6-112
 
23. Wong LP, Wong YL, Low WY, Khoo EM, Shuib R. Knowledge and awareness of cervical cancer and screening among Malaysian women who have never had a Pap smear: a qualitative study. Singapore Med J 2009; 50:49-53.
PMid:19224084
 
24. Mupepi SC, Sampselle CM, Johnson TR. Knowledge, attitudes, and demographic factors influencing cervical cancer screening behavior of Zimbabwean women. J Womens Health (Larchmt) 2011; 20:943-52.
http://dx.doi.org/10.1089/jwh.2010.2062
 
25. Osborne C, Ostir GV, Du X, Peek MK, Goodwin JS. The influence of marital status on the stage at diagnosis, treatment, and survival of older women with breast cancer. Breast Cancer Res Treat 2005; 93:41-7.
http://dx.doi.org/10.1007/s10549-005-3702-4
 
26. e Silva IT, Griep RH, Rotenberg L. Social support and cervical and breast cancer screening practices among nurses. Rev Lat Am Enfermagem 2009; 17:514-21.
http://dx.doi.org/10.1590/S0104-11692009000400013
 
27. Gamarra CJ, Paz EP, Griep RH. Social support and cervical and breast cancer screening in Argentinean women from a rural population. Public Health Nurs 2009; 26:269-76.
http://dx.doi.org/10.1111/j.1525-1446.2009.00779.x
 
28. Seow A, Huang J, Straughan PT. Effects of social support, regular physician and health-related attitudes on cervical cancer screening in an Asian population. Cancer Causes Control 2000; 11:223-30.
http://dx.doi.org/10.1023/A:1008954606992
 

Incidence of hydronephrosis in severe uterovaginal or vault prolapse

Share this Article

Singapore Med J 2013; 54(3): 160-162; http://dx.doi.org/doi:10.11622/smedj.2013048
Incidence of hydronephrosis in severe uterovaginal or vault prolapse

Wee WW, Wong HF, Lee LC, Han HC
Correspondence: Dr Wee Wei-Wei, wcube@hotmail.com

ABSTRACT
Introduction We aimed to evaluate the local incidences of hydronephrosis and renal impairment in the presence of severe uterovaginal or vault prolapse, and determine whether treatment by surgery or ring pessary resulted in the resolution of hydronephrosis in these patients.
Methods This was a retrospective case study of 121 patients who presented with severe uterovaginal or vault prolapse. All patients who had fourth degree uterovaginal or vault prolapse, and underwent renal ultrasonography and renal function blood tests were included in the study. Follow-up imaging for hydronephrosis was performed to determine the outcome after patients received treatment.
Results The mean age of the study population was 66.1 years. The overall incidence of hydronephrosis was 20.6%. The incidence of hydronephrosis in patients with severe vault prolapse was 7.1%, while that in patients with severe uterovaginal prolapse was 22.4%. Of the 25 patients with hydronephrosis, 16 (64.0%) had complete resolution of hydronephrosis after treatment, 5 (20.0%) had residual but smaller degrees of hydronephrosis, and 4 (16.0%) were lost to follow-up. The incidence of renal impairment was 3.3%.
Conclusion The local incidence of hydronephrosis in patients with severe uterovaginal or vault prolapse was 20.6% in our study. We established that 3.3% of women with severe uterovaginal or vault prolapse had mild renal impairment. Treatment by vaginal surgery for severe uterovaginal or vault prolapse appears to result in either complete resolution or improvement of hydronephrosis in the majority of patients.

Keywords: hydronephrosis, incidence, prolapse, uterovaginal, vault
Singapore Med J 2013; 54(3): 160-162; doi:10.11622/smedj.2013048

REFERENCES

1. Beverly CM, Walters MD, Weber AM, Piedmonte MR, Ballard LA. Prevalence of hydronephrosis in patients undergoing surgery for pelvic organ prolapse. Obstet Gynecol 1997; 90:37-41.
http://dx.doi.org/10.1016/S0029-7844(97)00240-8

 
2. Moore S, Bailey RR, Maling TM, Little PJ. Urinary tract obstruction and renal failure due to uterine prolapse. N Z Med J 1978; 87:429-31.
PMid:277808
 
3. Gemer O, Bergman M, Segal S. Prevalence of hydronephrosis in patients with genital prolapse. Eur J Obstet Gynecol Reprod Biol 1999; 86:11-3.
http://dx.doi.org/10.1016/S0301-2115(99)00052-4
 
4. Hui SY, Chan SC, Lam SY, Lau TK, Chung KH. A prospective study on the prevalence of hydronephrosis in women with pelvic organ prolapse and their outcomes after treatment. Int Urogynecol 2011; 22:1529-34.
http://dx.doi.org/10.1007/s00192-011-1504-2
 
5. Baden WF, Walker T. Fundamentals, symptoms, and classification. In: Baden WF, Walker T, eds. Surgical Repair of Vaginal Defects. Philadelphia: Lippincott, 1992: 9-23.
 
6. Churchill DN, Afridi S, Dow D, McManamon P. Uterine prolapse and renal dysfunction. J Urol 1980; 124:899-900.
PMid:7441844
 

Greater palatine foramen - key to successful hemimaxillary anaesthesia: a morphometric study and report of a rare aberration

Share this Article

Singapore Med J 2013; 54(3): 152-159; http://dx.doi.org/doi:10.11622/smedj.2013052
Greater palatine foramen - key to successful hemimaxillary anaesthesia: a morphometric study and report of a rare aberration

Sharma NA, Garud RS
Correspondence: Dr Namita Sharma, drnamitaalok@gmail.com

ABSTRACT
Introduction Accurate localisation of the greater palatine foramen (GPF) is imperative while negotiating the greater palatine canal for blocking the maxillary nerve within the pterygopalatine fossa. The aim of this study was to define the position of the foramen relative to readily identifiable intraoral reference points in order to help clinicians judge the position of the GPF in a consistently reliable manner.
Methods The GPF was studied in 100 dried, adult, unsexed skulls from the state of Maharashtra in western India. Measurements were made using a vernier calliper.
Results The mean distances of the GPF from the midline maxillary suture, incisive fossa, posterior palatal border and pterygoid hamulus were 14.49 mm, 35.50 mm, 3.40 mm and 11.78 mm, respectively. The foramen was opposite the third maxillary molar in 73.38% of skulls, and the direction in which the foramen opened into the oral cavity was found to be most frequently anteromedial (49.49%). In one skull, the greater and lesser palatine foramina were bilaterally absent. Except for the invariably present incisive canals, there were no accessory palatal foramina, which might have permitted passage of the greater palatine neurovascular bundle in lieu of the absent GPF. To the best of our knowledge, this is the first study of such a non-syndromic presentation.
Conclusion The GPF is most frequently palatal to the third maxillary molar. For an edentulous patient, the foramen may be located 14–15 mm from the mid-palatal raphe or about 12 mm anterior to the palpable pterygoid hamulus.

Keywords: greater palatine canal, greater palatine foramen, hard palate, maxillary nerve block, pterygopalatine fossa
Singapore Med J 2013; 54(3): 152-159; doi:10.11622/smedj.2013052

REFERENCES

1. Hawkins JM, Isen D. Maxillary nerve block: the pterygopalitine canal approach. J Calif Dent Assoc 1998; 26:658-64.
PMid:9879234
 
2. Standring S, Ellis H, Healy JC, et al, eds. Oral cavity. In: Gray's Anatomy: The Anatomical Basis of Clinical Practice. 39th Ed. London: Elsevier, Churchill Livingstone, 2005: 584.
 
3. Blanton PL, Jeske AH. The key to profound local anesthesia: neuroanatomy. J Am Dent Assoc 2003; 134:753-60.
PMid:12839412
 
4. Langford RJ. The contribution of the nasopalatine nerve to sensation of the hard palate. Br J Oral Maxillofac Surg 1989; 27:379-86.
http://dx.doi.org/10.1016/0266-4356(89)90077-6
 
5. Howard-Swirzinski K, Edwards PC, Saini TS, Norton NS. Length and geometric patterns of the greater palatine canal observed in cone beam computed tomography. Int J Dent 2010; pii: 292753.
http://dx.doi.org/10.1155/2010/292753
 
6. Methathrathip D, Apinhasmit W, Chompoopong S, et al. Anatomy of greater palatine foramen and canal and pterygopalatine fossa in Thais: considerations for maxillary nerve block. Surg Radiol Anat 2005; 27:511-6.
http://dx.doi.org/10.1007/s00276-005-0016-5
 
7. Malamed SF. Handbook of Local Anesthesia. 5th ed. St. Louis: Elsevier Mosby, 2004.
 
8. Ajmani ML. Anatomical variation in position of the greater palatine foramen in the adult human skull. J Anat 1994; 184:635-7.
PMid:7928651 PMCid:1259972
 
9. Westmoreland EE, Blanton PL. An analysis of the variations in position of the greater palatine foramen in the adult human skull. Anat Rec 1982; 204:383-8.
http://dx.doi.org/10.1002/ar.1092040412
 
10. Malamed SF, Trieger N. Intraoral maxillary nerve block: an anatomical and clinical study. Anesth Prog 1983; 30:44-8.
PMid:6587797 PMCid:2515480
 
11. Saralaya V, Nayak SR. The relative position of the greater palatine foramen in dry Indian skulls. Singapore Med J 2007; 48:1143-6.
PMid:18043845
 
12. Wang TM, Kuo KJ, Shih C, Ho LL, Liu JC. Assessment of the relative locations of the greater palatine foramen in adult Chinese skulls. Acta Anat (Basel) 1988; 132:182-6.
http://dx.doi.org/10.1159/000146572
 
13. Klosek SK, Rungruang T. Anatomical study of the greater palatine artery and related structures of the palatal vault: considerations for palate as the sub epithelial connective tissue graft donor site. Surg Radiol Anat 2009; 31:245-50.
http://dx.doi.org/10.1007/s00276-008-0432-4
 
14. Chrcanovic BR, Custódio AL. Anatomical variation in the position of the greater palatine foramen. J Oral Sci 2010; 52:109-13.
http://dx.doi.org/10.2334/josnusd.52.109
 
15. Sujatha N, Manjunath KY, Balasubramanyam V. Variations of the location of the greater palatine foramina in dry human skulls. Indian J Dent Res 2005; 16:99-102.
PMid:16454323
 
16. Hassanali J, Mwaniki D. Palatal analysis and osteology of the hard palate of the Kenyan African skulls. Anat Rec 1984; 209:273-80.
http://dx.doi.org/10.1002/ar.1092090213
 
17. Aterkar S, Rawal PM, Kumar P. Position of greater palatine foramen in adults. J Anat Soc India 1995; 44:126-33.
 
18. Bharadwaj VK, Novotny GM. Greater palatine canal injection: an alternative to the posterior nasal packing and arterial ligation in epistaxis. J Otolaryngol 1986; 15:94-100.
PMid:3520001
 
19. McHugh DA, Rose GE, Garner A. Nasolacrimal obstruction and facial bone histopathology in craniodiaphyseal dysplasia. Br J Ophthalmol 1994; 78:501-3.
http://dx.doi.org/10.1136/bjo.78.6.501
 
20. Van Hul W, Balemans W, Van Hul E, et al. Van Buchem disease (hyperostosis corticalis generalisata) maps to chromosome 17q12-q21. Am J Hum Genet 1998; 62:391-9.
http://dx.doi.org/10.1086/301721
 
21. McKenzie J, Craig J. Mandibulo-facial dysostosis (Treacher Collins syndrome) Arch Dis Child 1955; 30:391-5.
http://dx.doi.org/10.1136/adc.30.152.391
 
22. Behrents RG, McNamara JA, Avery JK. Prenatal mandibulofacial dysostosis (Treacher Collins syndrome). Cleft Palate J 1977; 14:13-34.
PMid:264276
 
23. Herring SW, Rowlatt UF, Pruzansky S. Anatomical abnormalities in mandibulofacial dysostosis. Am J Med Genet 1979; 3:225-9.
http://dx.doi.org/10.1002/ajmg.1320030303
 
24. Carstens MH. Neural tube programming and the pathogenesis of craniofacial clefts. Part II: mesenchyme, pharyngeal arches, developmental fields; and the assembly of the human face. In: Sarnat HB, Curatolo P, eds. Handbook of Clinical Neurology. London: Elsevier, 2008: chapter 17.
 
25. Ewings EL, Carstens MH. Neuroembryology and functional anatomy of craniofacial clefts. Indian J Plast Surg 2009; 42:19-34.
http://dx.doi.org/10.4103/0970-0358.57184
 

Variations in the posterior division branches of the mandibular nerve in human cadavers

Share this Article

Singapore Med J 2013; 54(3): 149-151; http://dx.doi.org/doi:10.11622/smedj.2013051
Variations in the posterior division branches of the mandibular nerve in human cadavers

Balaji T, Sharmila Saran R, Vaithianathan G, Aruna S
Correspondence: Dr Thotakura Balaji, balajitk@yahoo.com

ABSTRACT
Introduction The lingual, inferior alveolar and auriculotemporal nerves, being branches of the posterior division of the mandibular nerve, mainly innervate the mandibular teeth and all the major salivary glands. Anomalous communications among these branches are widely reported due to their significance to various treatment procedures undertaken in the region. This study was performed as detailed exploration of the functional perspectives of such communicating branches would further enhance the scope of these procedures.
Methods A total of 36 specimens were dissected to examine the infratemporal region. The branches from the posterior division of the mandibular nerve – namely the lingual, inferior alveolar and auriculotemporal nerves – were carefully dissected, and their branches were studied and analysed for abnormal course.
Results Communication between branches of the posterior division of the mandibular nerve was observed in four specimens. In two of the four specimens, communication between the mylohyoid and lingual nerves was observed. A rare and seldom reported type of communication between the auriculotemporal and inferior alveolar nerves is described in this study. This communicating nerve split into two to form a buttonhole for the passage of the mylohyoid nerve.
Conclusion Such communicating branches between nerves found in this study are developmental in origin and thought to maintain functional integrity through an alternative route.

Keywords: auriculotemporal, inferior alveolar, lingual, mandibular, mylohyoid
Singapore Med J 2013; 54(3): 149-151; doi:10.11622/smedj.2013051

REFERENCES

1. Berkovitz BK. Infratemporal region and temporomandibular joint. In: Standring S, ed. Gray's Anatomy: The Anatomical Basis of Clinical Practice. 39th ed. Edinburgh: Elsevier Churchill Livingstone, 2005: 526-30.
 
2. Siéssere S, Hallak Regalo SC, Semprini M, et al. Anatomical variations of the mandibular nerve and its branches correlated to clinical situations. Minerva Stomatol 2009; 58:209-15.
PMid:19436250
 
3. Rácz L, Maros T. [The anatomic variants of the lingual nerve in human.] Anat Anz 1981; 149:64-71. German.
PMid:7235270
 
4. Anil A, Peker T, Turgut HB, Gülekon IN, Liman F. Variations in the anatomy of the inferior alveolar nerve. Br J Oral Maxillofac Surg 2003; 41:236-9.
http://dx.doi.org/10.1016/S0266-4356(03)00113-X
 
5. Baumel JJ, Vanderheiden JP, McElenney JE. The auriculotemporal nerve of man. Am J of Anat 1971; 130:431-40.
http://dx.doi.org/10.1002/aja.1001300405
 
6. Fazan VPS, Rodrigues Filho OA, Matamala F. Communication between the mylohyoid and lingual nerves: clinical implications. Int J Morphol 2007; 25:561-4.
http://dx.doi.org/10.4067/S0717-95022007000300015
 
7. Kocabiyik N, Varol A, Sencimen M, Ozan H. An unnamed branch of the lingual nerve: gingival branch. Br J Oral Maxillofac Surg 2009; 47:214-7.
http://dx.doi.org/10.1016/j.bjoms.2008.07.197
 
8. Madeira MC, Percinoto C, das Graças M Silva M. Clinical significance of supplementary innervation of the lower incisor teeth: a dissection study of the mylohyoid nerve. Oral Surg Oral Med Oral Pathol 1978; 46:608-14.
http://dx.doi.org/10.1016/0030-4220(78)90455-3
 
9. Joshi A, Rood JP. External neurolysis of the lingual nerve. Int J Oral Maxillofac Surg 2002; 31:40-3.
http://dx.doi.org/10.1054/ijom.2001.0156
 
10. Potu BK, Pulakunta T, Ray B, et al. Unusual communication between the lingual nerve and mylohyoid nerves in a South Indian male cadaver: its clinical significance. Rom J Morphol Embryol 2009; 50:145-6.
PMid:19221662
 
11. Mascaro MB, Picoli LC, Santos FM, et al. Anatomical variation of the anterior belly of the digastric muscle: case report and clinical implications. J Morphol Sci 2011; 28:72-5.
 
12. Furusawa K, Yamaoka M, Fujimoto K, Kumai T. Role of proprioceptors in the mylohyoid muscle. Brain Res Bull 1994; 35:233-6.
http://dx.doi.org/10.1016/0361-9230(94)90127-9
 
13. Roy TS, Sarkar AK, Panicker HK. Variation in the origin of the inferior alveolar nerve. Clin Anat 2002; 15:143-7.
http://dx.doi.org/10.1002/ca.1110
 
14. Gülekon N, Anil A, Poyraz A et al. Variations in the anatomy of the auriculotemporal nerve. Clin Anat 2005; 18:15-22.
http://dx.doi.org/10.1002/ca.20068
 
15. Pai MM, Swamy RS, Prabhu LV. A variation in the morphology of the inferior alveolar nerve with potential clinical significance. Biomed Int 2010; 1:93-5.
 
16. Segade LA, Suarez Quintanilla D, Suarez Nu-ez JM. The postganglionic parasympathetic fibers originating in the otic ganglion are distributed in several branches of the trigeminal mandibular nerve: an HRP study in the guinea pig. Brain Res 1987; 411:386-90.
http://dx.doi.org/10.1016/0006-8993(87)91092-4
 
17. Takemura M, Sugimoto T, Sakai A. Topographic organization of central terminal region of different sensory branches of the rat mandibular nerve. Exp Neurol 1987; 96:540-57.
http://dx.doi.org/10.1016/0014-4886(87)90217-2
 

Sleeping posture and intraocular pressure

Share this Article

Singapore Med J 2013; 54(3): 146-148; http://dx.doi.org/doi:10.11622/smedj.2013050
Sleeping posture and intraocular pressure

Wong MH, Lai AH, Singh M, Chew PT
Correspondence: A/Prof Paul TK Chew, ophchewp@nus.edu.sg

ABSTRACT
Introduction This prospective observational case series aimed to determine whether the lateral decubitus position, which is commonly adopted during sleep, has an effect on intraocular pressure (IOP) in normal controls.
Methods Patients without glaucoma were recruited from those visiting outpatient clinics for non-glaucomatous conditions. The left eye of each patient was included. IOP was first measured using Tono-Pen® XL applanation tonometer in the supine position, following which a second measurement was immediately obtained for the left lateral head position. Measurements were obtained with the patient lying on one soft and one hard pillow for each position, and patients remained awake during these measurements. One tonometry reading was obtained for each position. Readings were recorded only when the average of four independent readings produced a statistical confidence index of 5%. Results were analysed using the paired Student’s t-test for comparison of the means.
Results IOP in the left lateral decubitus position (17.48 ± 3.18 mmHg) was significantly higher than in the supine position (14.48 ± 3.09 mmHg) when using soft pillows (p < 0.001). When hard pillows were used, IOP in the left lateral decubitus position also exceeded that measured in the supine position (16.65 ± 3.54 mmHg vs. 13.65 ± 3.58 mmHg; p < 0.001). There was no statistically significant difference in the IOPs measured for the same position when different kinds of pillows were used.
Conclusion The lateral decubitus position adopted during sleep is associated with changes in IOP in healthy volunteers.

Keywords: intraocular pressure, sleeping posture
Singapore Med J 2013; 54(3): 146-148; doi:10.11622/smedj.2013050

REFERENCES

1. Musch DC, Gillespie BW, Niziol LM, et al. Factors associated with intraocular pressure before and during 9 Years of treatment in the Collaborative Initial Glaucoma Treatment Study. Ophthalmology 2008; 115:927-33.
http://dx.doi.org/10.1016/j.ophtha.2007.08.010
 
2. Prata TS, De Moraes CG, Kanadani FN, Ritch R, Paranhos A Jr. Posture induced intraocular pressure changes: considerations regarding body position in glaucoma patients. Surv Ophthalmol 2010; 55:445-53.
http://dx.doi.org/10.1016/j.survophthal.2009.12.002
 
3. Hara T, Hara T, Tsuru T. Increase of peak intraocular pressure during sleep in reproduced diurnal changes by posture. Arch Ophthalmol 2006; 124:165-8.
http://dx.doi.org/10.1001/archopht.124.2.165
 
4. Kiuchi T, Motoyama Y, Oshika T. Relationship of progression of visual field damage to postural changes in intraocular pressure in patients with normal-tension glaucoma. Ophthalmology 2006; 113:2150-5.
http://dx.doi.org/10.1016/j.ophtha.2006.06.014
 
5. Mehdizadeh M. Sleep position and eye pressure. Ophthalmology 2007; 114:2632; author reply 2632.
http://dx.doi.org/10.1016/j.ophtha.2007.05.030
 
6. Korenfeld MS, Dueker DK. Occult intraocular pressure elevation and optic cup asymmetry, sleep posture may be a risk factor. Invest Ophthalmol Vis Sci 1993; 34(suppl):994.
 
7. Liu JH, Kripke DF, Hoffman RE, et al. Nocturnal elevation of intraocular pressure in young adults. Invest Ophthalmol Vis Sci 1998; 39:2707-12.
PMid:9856781
 
8. Evans D.W, Harris A, Garrett M, Chung HS, Kagemann L. Glaucoma patients demonstrate faulty autoregulation of ocular blood flow during posture change. Br J Ophthalmol 1999; 83:809-13.
http://dx.doi.org/10.1136/bjo.83.7.809